Musashino Red Cross Hospital

One‐Year Clinical Outcomes of Paclitaxel‐Coated Balloon Angioplasty in Patients With and Without Acute Coronary Syndrome: The ALLIANCE Registry

ABSTRACT Background Real‐world data after percutaneous coronary intervention (PCI) using drug‐coated balloons (DCBs) in acute coronary syndrome (ACS) are limited. Aims We compared 1‐year clinical outcomes after PCI with paclitaxel DCBs between the ACS and non‐ACS patients. Method...

2026 revised CVIT clinical expert consensus on drug coated balloons for coronary artery disease

Abstract Drug-coated balloons (DCBs) are attracting attention as a therapeutic alternative to drug-eluting stents (DES) in percutaneous coronary interventions. DCB technology allows direct delivery of antiproliferative drugs to the vessel wall without implantation of a permanent...

The “Dove Drawing” Appearance of the Ilium in Spondyloepiphyseal Dysplasia Congenita: A Proposed Radiographic Sign

Recognizable radiographic signs aid in the differential diagnosis of skeletal dysplasias. Spondyloepiphyseal dysplasia congenita (SEDC), a COL2A1-related disorder, presents with characteristic but sometimes subtle pelvic changes in early childhood. To propose a novel pelvic radio...

Exploratory analysis of IFN-α-high and CXCL9-high cytokine distributions in systemic lupus erythematosus-associated macrophage activation syndrome

Macrophage activation syndrome (MAS) is a life-threatening hyperinflammatory complication of systemic lupus erythematosus (SLE), but its immunopathology remains poorly understood. We investigated cytokine-associated inflammatory heterogeneity in SLE-associated MAS (SLE-MAS). Seru...

Evaluation of the UK Myeloma Research Alliance risk profile in transplant‐ineligible multiple myeloma patients treated with novel agents

Summary The heterogeneity of multiple myeloma (MM) significantly impacts treatment outcomes. Myeloma risk profile (MRP), introduced by the UK Myeloma Research Alliance, is a novel prognostic model for patients with transplant‐ineligible newly diagnosed MM (TIE‐NDMM) utilizing eas...